Baidu
map

Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

Kaye, KS; Boucher, HW; Brown, ML; Aggrey, A; Khan, I; Joeng, HK; Tipping, RW; Du, JJ; Young, K; Butterton, JR; Paschke, A

Paschke, A (corresponding author), Merck & Co Inc, Kenilworth, NJ 07033 USA.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020; 64 (5):

Abstract

The RESTORE-IMI 1 phase 3 trial demonstrated the efficacy and safety of imipenem-cilastatin (IMI) combined with relebactam (REL) for treating imipenem......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

Baidu
map
Baidu
map
Baidu
map